2 days ago · Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset collaboration with Neurocrine Biosciences. Osavampator, formerly known as NBI ...

4 days ago · About the Collaboration with Takeda In 2020, Neurocrine Biosciences and Takeda entered into a strategic collaboration to develop and commercialize compounds in depression and schizophrenia, including an exclusive license to both osavampator and NBI-1070770, which are being studied for the treatment of major depressive disorder, as well as a ...

Jun 16, 2020 · SAN DIEGO and Osaka, Japan, June 16, 2020 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a strategic collaboration to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline.

2 days ago · On Monday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the ...

3 days ago · Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended agreement ...

2 days ago · Neurocrine Biosciences on Monday announced that it will now have the exclusive worldwide right to develop and commercialize the drug candidate osavampator, which it had been developing with Takeda for major depressive disorder patients with subpar response to treatments.. The news comes amid an amended contract between Neurocrine and Takeda. The partners first entered into a neuroscience ...

3 days ago · SAN DIEGO, Jan. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric ...

Apr 3, 2024 · Neurocrine Biosciences acquired the rights to develop and commercialize NBI-1070770 from Takeda Pharmaceutical Company, Ltd. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options.

3 days ago · Neurocrine and Takeda, which is headquartered in Osaka, Japan, entered an agreement to develop and commercialize compounds for treatment of depression and schizophrenia in 2020.

4 days ago · Neurocrine Biosciences announced it has amended its agreement with Takeda to develop and commercialize osavampator. Under the amended agreement, Neurocrine will obtain exclusive rights for all ...